CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

MediWound Announces Completion of Patient Enrollment for Interim Assessment of the U.S. EscharEx Phase 2 Adaptive Design Study

Life Sciences Review Life Sciences Review | Friday, June 18, 2021
Tweet

MediWound announces that the enrollment target for an interim assessment of its EscharEx U.S. phase 2 adaptive design study to treat venous leg ulcers (VLUs) had been fulfilled.


FREMONT, CA: MediWound Ltd., a fully integrated biopharmaceutical firm dedicated to next-generation biotherapeutic solutions for tissue repair and regeneration, has announced that the enrollment target for an interim assessment of its EscharEx U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs) has been fulfilled, and interim assessment would be completed by the end of July 2021. The pre-determined interim assessment aims to conduct a futility analysis and possibly modify the sample size. This trial, which aims to enrol 120 patients by the end of 2021, will evaluate the safety and effectiveness of EscharEx to a gel vehicle (placebo control) and non-surgical standard-of-care (either enzymatic or autolytic debridement).


"We are very pleased to reach this important clinical milestone, and we look forward to the interim assessment next month," said Sharon Malka, Chief Executive Officer of MediWound. "With a clear unmet medical need for a non-surgical rapid and effective debridement agent in the outpatient setting, EscharEx has the potential to improve on the current standard of care and have a meaningful impact on chronic wound management. 


EscharEx represents a significant market opportunity for MediWound, with an addressable market of over a billion dollars annually."


MediWound is also undertaking a phase 2 open-label, single-arm research to examine the pharmacological effects of EscharEx in up to 15 patients with both diabetic foot ulcers (DFUs) and VLUs as part of its broader EscharEx development program. 


MediWound is also undertaking a phase 2 open-label, single-arm research to examine the pharmacological effects of EscharEx in up to 15 patients with both diabetic foot ulcers (DFUs) and VLUs as a part of its broader EscharEx development program. This study expects to learn more about what happens in the wound bed during and after EscharEx debridement and to analyze its impact on biofilm burden, inflammation decrease and wound healing initiation. The results of this study are expected in the second half of 2021, according to MediWound.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/mediwound-announces-completion-of-patient-enrollment-for-interim-assessment-of-the-us-escharex-phase-2-adaptive-design-study-nwid-404.html